CoChat
Sign Up
Cited by 8Pharmacology and Obesity TreatmentDiabetes Treatment and ManagementBariatric Surgery and Outcomes

The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities

Open access
Ganamurali, Nila, Sabarathinam, Sarvesh·2026·Clinical Pharmacology in Drug Development
DOI 10.1002/cpdd.70001
Open this paper in CoChat — free accountOpen PDF

Abstract

Obesity has emerged as a global health crisis requiring innovative therapeutic strategies beyond conventional approaches. While glucagon-like peptide-1 (GLP-1) and dual GIP/GLP-1 receptor agonists have redefined pharmacological management, their limitations necessitate further innovation. Retatrutide (LY3437943), a novel triple agonist targeting GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors, represents a transformative advance in obesity pharmacotherapy. Phase 2 trials report unprecedented weight reductions, comparable to bariatric surgery, with additional benefits for metabolic comorbidities such as NASH and cardiovascular disease. Retatrutide exemplifies rational multi-agonist peptide engineering and signals a paradigm shift in systems pharmacology. This perspective underscores the urgent need for scientific engagement, equity considerations, and policy preparedness, positioning retatrutide as a watershed in obesity treatment and a blueprint for future poly-agonist therapies.

Integrity signals

Registry

Crossref · 10.1002/cpdd.70001

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

16 of 35 cited sources checked · 8 supported · 0 flagged · accuracy not yet measured

  • Premisecitation

    Semaglutide 2.4 mg weekly led to a mean placebo-adjusted body weight reduction of 12.4% at 68 weeks in adults with obesity.

    “In STEP-1, weekly semaglutide 2.4 mg led to a mean placebo-adjusted body weight reduction of 12.4% at 68 weeks in adults with obesity, with significant improvements in cardiometabolic risk factors.19”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [19] 19. Wilding JPH, Batterham RL, Calanna S, et al. Once- weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. source
  • Interpretationcitation

    Multi-agonist therapies mark a paradigm shift in obesity treatment, offering a more integrated and durable approach to managing this complex disease in a way that current single-target strategies cannot achieve.

    “Thus, multi-agonist therapies mark a paradigm shift in obesity treatment, offering a more integrated and durable approach to managing this complex disease in a way that current single-target strategies cannot achieve.15”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [15] 15. Srivastava G, Campbell SL, Hill CR, et al. Novel strate- gies for medical management of obesity: mechanisms, clinical implications, and societal impacts-a report from the 25th Annual Harvard Nutrition Obesity Sym- posium. Am J Clin Nutr. 2025;122(3):866-885. source

      Session I (page unavailable) describes dual- and triple-receptor therapies that act on complementary pathways and reports promising weight-loss results. It says a triple agonist could be more effective and shows potential for sustained weight loss, but does not establish that multi-agonist treatment is durably effective in a way single-target treatment cannot achieve. (LLM, conf=0.87)

      Experimental — accuracy not yet measured
  • Premisecitation

    These agents show potential to address the broader spectrum of obesity-related complications, including non-alcoholic fatty liver disease and cardiovascular dysfunction.

    “Beyond weight reduction, these agents show potential to address the broader spectrum of obesity-related complications, including non-alcoholic fatty liver disease and cardiovascular dysfunction.10,11”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [10] 10. Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide- 1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234. source
    • cites [11] 11. Alfaris N, Waldrop S, Johnson V, Boaventura B, Kendrick K, Stanford FC. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review. EClinicalMedicine. 2024;75:102782. source
  • Premisecitation

    In silico modeling, in vitro receptor binding studies, and in vivo trials in both rodents and humans have demonstrated that receptor cross-talk and synergistic signaling can be exploited rather than avoided.

    “Importantly, in silico modeling, in vitro receptor binding studies, and in vivo trials in both rodents and humans have demonstrated that receptor cross-talk and synergistic signaling can be exploited rather than avoided.”
    Quote in the paperSubstantial claim1 of 3 sources checked
    • cites [42] 42. Abdul-Rahman T, Roy P, Ahmed FK, et al. The power of three: retatrutide's role in modern obesity and diabetes therapy. Eur J Pharmacol. 2024;985:177095. source
    • cites [43] 43. Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of ran- domized controlled trials. Proc (Bayl Univ Med Cent). 2025;38(3):291-303. source

      The Discussion (page unavailable) says combining GLP-1 or GIP–GLP-1 agonism with glucagon receptor activation could enhance effectiveness, and the paper reports human retatrutide trials. It also mentions preclinical weight-loss findings in rodents. But our copy does not report in silico modeling or in vitro receptor-binding studies, and it does not establish receptor cross-talk or synergistic signaling as the demonstrated mechanism. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites [44] 44. Hughes RE, Elliott RJR, Dawson JC, Carragher NO. High-content phenotypic and pathway profiling to ad- vance drug discovery in diseases of unmet need. Cell Chem Biol. 2021;28(3):338-355. source
  • Premisecitation

    Retatrutide is a rationally engineered linear peptide analog optimized for high-affinity binding at GLP-1, GIP, and glucagon receptors.

    “Structurally, retatrutide is a rationally engineered linear peptide analog optimized for high-affinity binding at GLP-1, GIP, and glucagon(GCP) receptors.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [14] 14. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234- 1247.e9. source
  • May combine two claims. 13
  • Classified as probably not a substantial claim. 5
  • The quote only partly states this claim. 1

  • May combine two claims.

    Premisecitation

    Glucagon receptor activation increases hepatic glucose output but simultaneously boosts energy expenditure and fatty-acid oxidation.

    “Although glucagon receptor activation increases hepatic glucose output, it simultaneously boosts energy expenditure and fatty-acid oxidationeffects that become therapeutically advantageous when GLP-1R and GIPR signaling create an insulin-dominant hormonal environment.17”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [17] 17. Knerr PJ, Mowery SA, Douros JD, et al. Next gen- eration GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Mol Metab. 2022;63:101533. source

      The Conclusions link glucagon-receptor activity to possible increases in glycogenolysis and gluconeogenesis, and the Results report increased energy expenditure with the triple agonist in obese mice. The paper also says GLP-1R and GIPR activity can buffer glucagon’s hyperglycemic effects. It does not establish the claimed boost in fatty-acid oxidation. (LLM, conf=0.88)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Concurrent activation of GIP receptors amplifies incretin-mediated insulin secretion and improves nutrient partitioning toward adipocytes, thereby reducing hepatic lipotoxicity and enhancing insulin sensitivity.

    “Concurrent activation of GIP receptors further amplifies incretin-mediated insulin secretion and improves nutrient partitioning toward adipocytes, thereby reducing hepatic lipotoxicity and enhancing insulin sensitivity.16”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [16] 16. Nauck MA, D-Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrad- ing glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21(1):169. source

      The Mechanisms of action section (page unavailable) reports enhanced insulin secretion with tirzepatide and an inferred insulin-sensitizing effect of GIP-receptor activation. It describes preferential fat storage in subcutaneous adipose tissue and reduced ectopic liver fat only as potential mechanisms. The citing sentence presents that proposed pathway—and its reduction of hepatic lipotoxicity—as established. (LLM, conf=0.89)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Activation of GLP-1 receptors enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and lowers appetite, collectively reducing glycemic load.

    “Activation of GLP-1 receptors enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and lowers appetite, collectively reducing glycemic load.10”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [10] 10. Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide- 1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234. source

  • May combine two claims.

    Premisecitation

    Emerging reviews highlight the absence of cardiovascular-outcomes data and the necessity to evaluate pancreatic, hepatic, and cardiometabolic safety under prolonged GLP-1/GIP/GCGR stimulation before establishing retatrutide as a long-term therapeutic standard.

    “Additionally, emerging reviews highlight the absence of cardiovascularoutcomes data and the necessity to evaluate pancreatic, hepatic, and cardiometabolic safety under prolonged GLP-1/GIP/GCGR stimulation before establishing retatrutide as a long-term therapeutic standard.46”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [46] 46. Mullur N, Morissette A, Morrow NM, Mulvihill EE. GLP-1 receptor agonist-based therapies and cardio- vascular risk: a review of mechanisms. J Endocrinol. 2024;263(1):e240046. source

      Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Over 1 billion people now live with obesity.

    “Over 1 billion people now live with obesity, a driver of type 2 diabetes, cardiovascular disease, and certain cancers.”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [33] 33. Ng M, Gakidou E, Lo J, et al. Global, regional, and na- tional prevalence of adult overweight and obesity, 1990- 2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. The Lancet. 2025;405(10481):813-838. source

      The Results section, “Overweight and obesity prevalence in 2021” (page not provided), estimates 2.11 billion adults with overweight or obesity combined, not over 1 billion with obesity alone. The Results section, “Forecasts of adult overweight and obesity in 2050” (page not provided), forecasts 1.95 billion adults with obesity by 2050; that is not a current count. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    Obesity substantially increases the risk of diabetes, cardiovascular disease, fatty liver disease, and certain cancers.

    “Obesity substantially increases the risk of diabetes, cardiovascular disease, fatty liver disease, and certain cancers, while imposing enormous societal and economic burdens.[2][3][4]”
    Quote in the paperNot a substantial claim3 of 3 sources checked
    • cites [2] 2. Kong Y, Yang H, Nie R, et al. Obesity: patho- physiology and therapeutic interventions. Mol Biomed. 2025;6(1):25. source
    • cites [3] 3. Ruperez C, Madeo F, de Cabo R, Kroemer G, Abdellatif M. Obesity accelerates cardiovascular ageing. Eur Heart J. 2025;46(23):2161-2185. source

      The Introduction links obesity to increased cardiovascular risk, and the Figure 5 caption in the concluding remarks lists type 2 diabetes among conditions associated with obesity. The passages in our copy do not establish the claimed increased risk of fatty liver disease or certain cancers. (LLM, conf=0.87)

      Experimental — accuracy not yet measured
    • cites [4] 4. Ahmed SK, Mohammed RA. Obesity: Prevalence, causes, consequences, management, preventive strate- gies and future research directions. Metabolism Open. 2025;27:100375. source

  • May combine two claims.

    Premisecitation

    Even highly efficacious GLP-1 agonists face challenges, including variable response rates, gastrointestinal side effects, and weight regain after discontinuation.

    “Even highly efficacious GLP-1 agonists face challenges, including variable response rates, gastrointestinal side effects, and weight regain after discontinuation.”
    Quote in the paperSubstantial claim3 of 3 sources checked
    • cites [34] 34. Thomsen RW, Mailhac A, Løhde JB, Pottegård A. Real- world evidence on the utilization, clinical and compar- ative effectiveness, and adverse effects of newer GLP- 1RA-based weight-loss therapies. Diabetes Obes Metab. 2025;27 Suppl 2(Suppl 2):66-88. source
    • cites [35] 35. Reiss AB, Gulkarov S, Lau R, et al. Weight reduc- tion with GLP-1 agonists and paths for discontinuation while maintaining weight loss. Biomolecules. 2025;15(3): 408. source
    • cites [36] 36. Bushi G, Gaidhane S, Ballal S, et al. Association be- tween GLP1 RAs use and risk of colorectal cancer: a systematic review and meta-analysis. Health Sci Rep. 2025;8(2):e70490. source

      The Introduction describes GLP-1 receptor agonists as effective for type 2 diabetes, and the Discussion reports gastrointestinal side effects, including nausea and diarrhea. Neither passage establishes variable response rates or weight regain after discontinuation; the Discussion’s discontinuation rates concern stopping treatment because of side effects, not subsequent weight regain. Page numbers are unavailable in our copy. (LLM, conf=0.87)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Pharmacological profiling of retatrutide shows that its relative potency at GLP-1R and GIPR is sufficient to counterbalance glucagon-induced hepatic glucose production, allowing selective exploitation of glucagon's thermogenic and lipolytic actions without causing hyperglycemia.

    “Pharmacological profiling of retatrutide shows that its relative potency at GLP-1R and GIPR is sufficient to counterbalance glucagoninduced hepatic glucose production, allowing selective exploitation of glucagon's thermogenic and lipolytic actions without causing hyperglycemia.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [14] 14. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234- 1247.e9. source

  • May combine two claims.

    Premisecitation

    Retatrutide's sequence modifications prolong half-life, enhance stability against proteolysis, and support once-weekly subcutaneous administration.

    “Its sequence modifications prolong half-life, enhance stability against proteolysis, and support once-weekly subcutaneous administration.14”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [14] 14. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234- 1247.e9. source

  • May combine two claims.

    Premisecitation

    Gastrointestinal adverse events were the most common adverse events with retatrutide, particularly at higher doses, but were generally manageable and consistent with the GLP-1 drug class profile.

    “Gastrointestinal adverse events were the most common, particularly at higher doses, but were generally manageable and consistent with the GLP-1 drug class profile.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [49] 49. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity-a phase 2 trial. N Engl J Med. 2023;389(6): 514-526. source

  • May combine two claims.

    Premisecitation

    Retatrutide produced significant improvements in waist circumference, glycemic measures, lipid profiles, and hepatic steatosis.

    “In addition to weight reduction, significant improvements were observed in waist circumference, glycemic measures, lipid profiles, and hepatic steatosis, confirming the broad metabolic benefits of triple agonism.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [49] 49. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity-a phase 2 trial. N Engl J Med. 2023;389(6): 514-526. source

  • May combine two claims.

    Premisecitation

    Dual and triple agonists such as GLP-1/GIP or GLP-1/GIP/glucagon receptor agonists have demonstrated superior efficacy in reducing body weight, improving glycemic control, and enhancing lipid metabolism compared to traditional monotherapies.

    “Dual and triple agonists such as glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide (GLP-1/GIP) or GLP-1/GIP/glucagon receptor agonists have demonstrated superior efficacy in reducing body weight, improving glycemic control, and enhancing lipid metabolism compared to traditional monotherapies.9”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [9] 9. Sharma N, Khatib MN, Balaraman AK, et al. Effect of GLP-1 receptor agonists on prostate cancer risk reduc- tion: a systematic review and meta-analysis. Review. Int Urol Nephrol. 2025;57(4):1039-1049. source

  • May combine two claims.

    Interpretationreasoning

    Retatrutide's 48-week Phase 2 results indicate unprecedented efficacy, but the long-term durability and safety of triple-agonist therapy remain insufficiently defined.

    “Although retatrutide's 48week Phase 2 results indicate unprecedented efficacy, the long-term durability and safety of triple-agonist therapy remain insufficiently defined.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S2 (checkable), S4 (based).

    Interpretationreasoning

    Retatrutide signals a paradigm shift in systems pharmacology.

    “Retatrutide exemplifies rational multi-agonist peptide engineering and signals a paradigm shift in systems pharmacology.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). The quote only partly states this claim.

    Interpretationown data

    Retatrutide's weight reduction approached bariatric surgery outcomes.

    “approaching bariatric surgery outcomes.”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim.

    Premisecitation

    Obesity is a multifactorial chronic disease rather than a simple problem of excess fat storage.

    “Obesity is increasingly recognized as a multifactorial chronic disease rather than a simple problem of excess fat storage.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [1] 1. Delker E, AlYami B, Gallo LC, Ruiz JM, Szklo M, Allison MA. Chronic stress burden, visceral adi- pose tissue, and adiposity-related inflammation: the multi-ethnic study of atherosclerosis. Psychosom Med. 2021;83(8):834-842. source

  • May combine two claims.

    Interpretationreasoning

    Retatrutide has demonstrated weight reductions approaching those achieved with bariatric surgery, while also delivering broad metabolic improvements.

    “By integrating GLP-1, GIP, and glucagon receptor agonism into a single therapeutic agent, it has demonstrated weight reductions approaching those achieved with bariatric surgery, while also delivering broad metabolic improvements.”
    Quote in the paperSubstantial claim
17 of 17

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Glykofrydi S, 2000, Endotext
  2. Al Rashid S, 2025, Pharmacoeconomics of oral weight‐lowering drugs in type 2 diabetes: a comparative study of SGLT‐2 inhibitors and GLP‐1 analogues in India, TPM ‐ Testing, Psychometrics, Methodology in Applied Psychology, 32, 792

Cited by

Sorted by citations

Related

Authors
Ganamurali, N., & Sabarathinam, S.
Affiliations
Saveetha University (IN)
Corresponding author
Sabarathinam, Sarvesh
ORCID
Venue
Clinical Pharmacology in Drug Development
Publisher
Wiley
Published
2026-01
Volume
15
Issue
1
Pages
e70001-e70001
ISSN
  • 2160-763X (ISSN-L)
  • 2160-7648
DOI
10.1002/cpdd.70001
OpenAlex
W7124601358
Cited by
8
References
46
Citations by year
2026: 8
FWCI
8.26
Type
journal article
Language
en
Open access
Licence
Locations
  • Clinical Pharmacology in Drug Development (publishedVersion, public-domain)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
retatrutide, GLP-1 receptor agonists, GIP receptor agonist, glucagon receptor agonist, obesity pharmacotherapy, cardiometabolic comorbidities, nonalcoholic steatohepatitis, cardiovascular disease, weight loss, peptide engineering, systems pharmacology
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Animals, Cardiovascular Diseases, Fatty Acids, Gastric Inhibitory Polypeptide, Humans, Obesity, Peptides, Receptors, Gastrointestinal Hormone, Comorbidity, Receptors, Glucagon, Anti-Obesity Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-11.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-11.

Cited sources are checked by gpt-6-sol.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review